CTOs on the Move

Icosavax

www.icosavax.com

 
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.icosavax.com
  • 1616 Eastlake Avenue East Suite 208
    Seattle, WA USA 98102
  • Phone: 206.737.0085

Executives

Name Title Contact Details

Funding

Icosavax raised $51M on 10/03/2019

Similar Companies

NextImage Medical

NextImage Medical is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PreciThera

PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology.

MicroDose Therapeutx

MicroDose Therapeutx is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immusoft

Immusoft Corporation (immusoft.com) is a pre-clinical gene therapy company based in Seattle, Wash. Its mission is to treat diseases using its breakthrough technology platform called Immune System Programming.

Catamaran Bio

Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWINDTM Platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures and Astellas Venture Management.